https://www.selleckchem.com/products/GDC-0941.html
CPX-351, a liposomal encapsulation of cytarabine and daunorubicin at a synergistic 51 molar ratio, is indicated for adults with newly diagnosed, therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes. In preclinical species, this article demonstrated (1) similar release of cytarabine and daunorubicin by CPX-351 in plasma; (2) similar patterns of metabolism of cytarabine and daunorubicin following administration of CPX-351 versus non-liposomal cytarabine/daunorubicin combination; (3) prolong
Me gusta
Comentario
Compartir
